Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants.

Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis BL, Thomas SJ, Gibbons RV, Hengprasert S, Samakoses R, Kerdpanich A, Vaughn DW, Putnak JR, Eckels KH, Barrera Rde L, Mammen MP Jr.

Am J Trop Med Hyg. 2011 Aug;85(2):341-51. doi: 10.4269/ajtmh.2011.10-0501.

2.

Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate.

Anderson KB, Gibbons RV, Edelman R, Eckels KH, Putnak RJ, Innis BL, Sun W.

J Infect Dis. 2011 Aug 1;204(3):442-50. doi: 10.1093/infdis/jir279.

PMID:
21742844
3.

The necessity and quandaries of dengue vaccine development.

Thomas SJ.

J Infect Dis. 2011 Feb 1;203(3):299-303. doi: 10.1093/infdis/jiq060. No abstract available.

4.

Acute myocarditis in dengue hemorrhagic fever: a case report and review of cardiac complications in dengue-affected patients.

Lee IK, Lee WH, Liu JW, Yang KD.

Int J Infect Dis. 2010 Oct;14(10):e919-22. doi: 10.1016/j.ijid.2010.06.011. Epub 2010 Sep 18. Review.

5.

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.

Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J.

J Infect Dis. 2010 Feb 1;201(3):370-7. doi: 10.1086/649916.

PMID:
20059357
6.

Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance.

Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, Putnak R, Gibbons RV, Jarman R, Endy TP.

Am J Trop Med Hyg. 2009 Nov;81(5):825-33. doi: 10.4269/ajtmh.2009.08-0625.

7.

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.

Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW, Thomas SJ, Kanesa-Thasan N, Innis BL, Edelman R.

Hum Vaccin. 2009 Jan-Feb;5(1):33-40. Epub 2009 Jan 27.

PMID:
18670195
8.

A new quantitative RT-PCR method for sensitive detection of dengue virus in serum samples.

Sadon N, Delers A, Jarman RG, Klungthong C, Nisalak A, Gibbons RV, Vassilev V.

J Virol Methods. 2008 Oct;153(1):1-6. doi: 10.1016/j.jviromet.2008.06.023. Epub 2008 Aug 8.

PMID:
18652847
9.

Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.

Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL, Sun W, Putnak JR, Eckels KH, Hutagalung Y, Gibbons RV, Zhang C, De La Barrera R, Jarman RG, Chawachalasai W, Mammen MP Jr.

Am J Trop Med Hyg. 2008 Mar;78(3):426-33.

PMID:
18337339
10.

Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS).

Pang T, Cardosa MJ, Guzman MG.

Immunol Cell Biol. 2007 Jan;85(1):43-5. Epub 2006 Nov 28. Review.

PMID:
17130899
11.

Race: a risk factor for dengue hemorrhagic fever.

de la C Sierra B, Kourí G, Guzmán MG.

Arch Virol. 2007;152(3):533-42. Epub 2006 Nov 16.

PMID:
17106622
12.

Cost-effectiveness of a pediatric dengue vaccine.

Shepard DS, Suaya JA, Halstead SB, Nathan MB, Gubler DJ, Mahoney RT, Wang DN, Meltzer MI.

Vaccine. 2004 Mar 12;22(9-10):1275-80.

PMID:
15003657
13.

Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command.

Innis BL, Eckels KH.

Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):1-4. Review. No abstract available. Erratum in: Am J Trop Med Hyg. 2004 Mar;70(3):336.

PMID:
14756126
14.

Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.

Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, Kanesa-Thasan N, Vaughn DW, Innis BL, Sun W.

Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):48-60. Erratum in: Am J Trop Med Hyg. 2004 Mar;70(3):336.

PMID:
14740955
15.

Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys.

Eckels KH, Dubois DR, Putnak R, Vaughn DW, Innis BL, Henchal EA, Hoke CH Jr.

Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):12-6. Erratum in: Am J Trop Med Hyg. 2004 Mar;70(3):336.

PMID:
14740950
16.

Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS.

Am J Trop Med Hyg. 2001 Nov;65(5):405-13.

PMID:
11716091
17.

Human skin Langerhans cells are targets of dengue virus infection.

Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, Louder MK, Filgueira L, Marovich MA, Wong HK, Blauvelt A, Murphy GS, Robb ML, Innes BL, Birx DL, Hayes CG, Frankel SS.

Nat Med. 2000 Jul;6(7):816-20.

PMID:
10888933
18.

Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.

Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A.

J Infect Dis. 2000 Jan;181(1):2-9.

PMID:
10608744
19.

Quantitative relationship between oral temperature and severity of illness following inoculation with candidate attenuated dengue virus vaccines.

Mackowiak PA, Wasserman SS, Tacket CO, Vaughn DW, Eckels KH, Dubois DR, Hoke CH, Edelman R.

Clin Infect Dis. 1994 Nov;19(5):948-50.

PMID:
7893886

Supplemental Content

Support Center